Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001688530-25-000001
Filing Date
2025-01-08
Accepted
2025-01-08 18:58:14
Documents
1
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 5977
  Complete submission text file 0001688530-25-000001.txt   7779
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Issuer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 1120 S CAPITAL OF TX HWY BLDG 1, STE 300 AUSTIN TX 78746
Business Address
Cavanaugh Stefanie L. (Reporting) CIK: 0001688530 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34810 | Film No.: 25519664